Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions		Total	Total CVS Health Shareholders’ Equity	Common Shares	Treasury Shares		Common Stock and Capital Surplus		Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2022				1,758
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2022	[1]				(458)
Balance at beginning of period at Dec. 31, 2022		$ 71,769	$ 71,469		$ (31,858)	[1]	$ 48,193	[2]	$ 56,398	$ (1,264)	$ 300
Shareholders' Equity [Roll Forward]
Net income		2,142	2,136						2,136		6
Other comprehensive income (loss)		389	389							389
Stock option activity, stock awards and other (in shares)				1
Stock option activity, stock awards and other		122	122				122	[2]
Purchases of treasury shares, net of ESPP issuances (in shares)	[1]				(22)
Purchase of treasury shares, net of ESPP issuances		(1,962)	(1,962)		$ (1,944)	[1]	(18)	[2]
Common stock dividends		(781)	(781)						(781)
Other increases (decreases) in noncontrolling interests		(99)	9				9	[2]			(108)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2023				1,759
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2023	[1]				(480)
Balance at end of period at Mar. 31, 2023		71,580	71,382		$ (33,802)	[1]	48,306	[2]	57,753	(875)	198
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2022				1,758
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2022	[1]				(458)
Balance at beginning of period at Dec. 31, 2022		71,769	71,469		$ (31,858)	[1]	48,193	[2]	56,398	(1,264)	300
Shareholders' Equity [Roll Forward]
Net income		6,321
Other comprehensive income (loss)		260
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2023				1,767
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2023	[1]				(480)
Balance at end of period at Sep. 30, 2023		74,510	74,337		$ (33,831)	[1]	48,829	[2]	60,343	(1,004)	173
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2023				1,759
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2023	[1]				(480)
Balance at beginning of period at Mar. 31, 2023		71,580	71,382		$ (33,802)	[1]	48,306	[2]	57,753	(875)	198
Shareholders' Equity [Roll Forward]
Net income		1,914	1,901						1,901		13
Other comprehensive income (loss)		17	17							17
Stock option activity, stock awards and other (in shares)				5
Stock option activity, stock awards and other		345	345				345	[2]
Purchases of treasury shares, net of ESPP issuances (in shares)	[1]				(2)
Purchase of treasury shares, net of ESPP issuances		(129)	(129)		$ (131)	[1]	2	[2]
Common stock dividends		(786)	(786)						(786)
Acquisition of noncontrolling interests		66									66
Other increases (decreases) in noncontrolling interests		(5)	(4)				(4)	[2]			(1)
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2023				1,764
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2023	[1]				(482)
Balance at end of period at Jun. 30, 2023		73,002	72,726		$ (33,933)	[1]	48,649	[2]	58,868	(858)	276
Shareholders' Equity [Roll Forward]
Net income		2,265	2,261						2,261		4
Other comprehensive income (loss)		(146)	(146)							(146)
Stock option activity, stock awards and other (in shares)				3
Stock option activity, stock awards and other		165	165				165	[2]
ESPP issuances, net of purchase of treasury shares (in shares)	[1]				2
ESPP issuances, net of purchase of treasury shares		105	105		$ 102	[1]	3	[2]
Common stock dividends		(786)	(786)						(786)
Other increases (decreases) in noncontrolling interests		(95)	12				12	[2]			(107)
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2023				1,767
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2023	[1]				(480)
Balance at end of period at Sep. 30, 2023		$ 74,510	74,337		$ (33,831)	[1]	48,829	[2]	60,343	(1,004)	173
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023				1,768
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023		(480)			(480)	[3]
Balance at beginning of period at Dec. 31, 2023		$ 76,636	76,461		$ (33,838)	[3]	48,992	[4]	61,604	(297)	175
Shareholders' Equity [Roll Forward]
Net income		1,124	1,113						1,113		11
Other comprehensive income (loss)		(44)	(44)							(44)
Stock option activity, stock awards and other (in shares)				3
Stock option activity, stock awards and other		244	244				244	[4]
Purchases of treasury shares, net of ESPP issuances (in shares)	[3]				(39)
Purchase of treasury shares, net of ESPP issuances		(2,962)	(2,962)		$ (2,935)	[3]	(27)	[4]
Common stock dividends		(844)	(844)						(844)
Other increases (decreases) in noncontrolling interests		(4)									(4)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2024				1,771
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2024	[3]				(519)
Balance at end of period at Mar. 31, 2024		$ 74,150	73,968		$ (36,773)	[3]	49,209	[4]	61,873	(341)	182
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023				1,768
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023		(480)			(480)	[3]
Balance at beginning of period at Dec. 31, 2023		$ 76,636	76,461		$ (33,838)	[3]	48,992	[4]	61,604	(297)	175
Shareholders' Equity [Roll Forward]
Net income		2,963
Other comprehensive income (loss)		$ 506
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2024				1,777
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2024		(519)			(519)	[3]
Balance at end of period at Sep. 30, 2024		$ 75,106	74,944		$ (36,813)	[3]	49,510	[4]	62,038	209	162
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2024				1,771
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2024	[3]				(519)
Balance at beginning of period at Mar. 31, 2024		74,150	73,968		$ (36,773)	[3]	49,209	[4]	61,873	(341)	182
Shareholders' Equity [Roll Forward]
Net income		1,768	1,770						1,770		(2)
Other comprehensive income (loss)		22	22							22
Stock option activity, stock awards and other (in shares)				6
Stock option activity, stock awards and other		159	159				159	[4]
Purchases of treasury shares, net of ESPP issuances (in shares)	[3]				(2)
Purchase of treasury shares, net of ESPP issuances		(143)	(143)		$ (146)	[3]	3	[4]
Common stock dividends		(846)	(846)						(846)
Other increases (decreases) in noncontrolling interests		1									1
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2024				1,777
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2024	[3]				(521)
Balance at end of period at Jun. 30, 2024		75,111	74,930		$ (36,919)	[3]	49,371	[4]	62,797	(319)	181
Shareholders' Equity [Roll Forward]
Net income		71	87						87		(16)
Other comprehensive income (loss)		528	528							528
Stock option activity, stock awards and other		138	138				138	[4]
ESPP issuances, net of purchase of treasury shares (in shares)	[3]				2
ESPP issuances, net of purchase of treasury shares		107	107		$ 106	[3]	1	[4]
Common stock dividends		(846)	(846)						(846)
Other increases (decreases) in noncontrolling interests		$ (3)									(3)
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2024				1,777
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2024		(519)			(519)	[3]
Balance at end of period at Sep. 30, 2024		$ 75,106	$ 74,944		$ (36,813)	[3]	$ 49,510	[4]	$ 62,038	$ 209	$ 162

[1] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of September 30, 2023, June 30, 2023, March 31, 2023 and December 31, 2022.

[2] Common stock and capital surplus includes the par value of common stock of $18 million as of September 30, 2023, June 30, 2023, March 31, 2023 and December 31, 2022.

[3] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of September 30, 2024, June 30, 2024, March 31, 2024 and December 31, 2023.

[4] Common stock and capital surplus includes the par value of common stock of $18 million as of September 30, 2024, June 30, 2024, March 31, 2024 and December 31, 2023.